AR089903A1 - Derivados de azetidina - Google Patents

Derivados de azetidina

Info

Publication number
AR089903A1
AR089903A1 ARP130100349A ARP130100349A AR089903A1 AR 089903 A1 AR089903 A1 AR 089903A1 AR P130100349 A ARP130100349 A AR P130100349A AR P130100349 A ARP130100349 A AR P130100349A AR 089903 A1 AR089903 A1 AR 089903A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloalkyl
cycloalkyl
halogen
hydrogen
Prior art date
Application number
ARP130100349A
Other languages
English (en)
Inventor
Anselm Lilli
Haap Wolfgang
Peters Jens
Uwe-Spinnler Beat
Luebbers Thomas
Kuhn Bernd
Banner David
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR089903A1 publication Critical patent/AR089903A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos útiles para tratar diabetes y enfermedades cardiovasculares. Reivindicación 1: Un compuesto de la fórmula (1) en la que: uno de A¹ y A² es -NR⁹- y el otro es -CH₂-; R¹ es halógeno; R² es hidrógeno, halógeno, alquilo o haloalquilo; R³ es hidrógeno, halógeno, alquilo o haloalquilo; R⁴ y R⁵ son ambos hidrógeno al mismo tiempo; o R⁴ y R⁵ junto con el átomo de carbono al que están unidos forman un cicloalquilo; R⁶ es hidrógeno, halógeno, alquilo, haloalquilo o cicloalquilo; R⁷ es hidrógeno, halógeno, alquilo, haloalquilo o cicloalquilo; R⁸ es hidrógeno, alquilo, haloalquilo, alcoxi, haloalcoxi, cicloalquilo, alquilpiridinilo, alquil-1H-pirazolilo fenilo, fenilo sustituido, heterociclo o heterociclilo sustituido, dicho heterociclilo es piridinilo, pirimidinilo, pirazinilo, piridazinilo, pirrolilo, pirazolilo, imidazolilo, triazolilo, oxazolilo, isoxazolilo, oxadiazolilo, tiofenilo, tiazolilo, tiadiazolilo, piperidinilo, piperazinilo, pirrolidinilo o morfolinilo, dicho fenilo sustituido es fenilo sustituido de una a tres veces por sustituyentes elegidos con independencia entre alquilo, halógeno, cicloalquilo, haloalquilo, alcoxi, haloalcoxi, halocicloalquilo y nitrilo y dicho heterociclilo sustituido es heterociclilo sustituido de una a tres veces por sustituyentes elegidos con independencia entre alquilo, halógeno, cicloalquilo, haloalquilo, alcoxi, haloalcoxi, halocicloalquilo y nitrilo; y R⁹ es hidrógeno, alquilo, haloalquilo, cicloalquilo, acilo o alcoxicarbonilo; o una sal o un éter farmacéuticamente aceptable del mismo.
ARP130100349A 2012-02-07 2013-02-05 Derivados de azetidina AR089903A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12154244 2012-02-07

Publications (1)

Publication Number Publication Date
AR089903A1 true AR089903A1 (es) 2014-09-24

Family

ID=47630385

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100349A AR089903A1 (es) 2012-02-07 2013-02-05 Derivados de azetidina

Country Status (11)

Country Link
US (1) US8822505B2 (es)
EP (1) EP2812322B1 (es)
JP (1) JP6096808B2 (es)
KR (1) KR20140120902A (es)
CN (1) CN104093713B (es)
AR (1) AR089903A1 (es)
BR (1) BR112014019180A8 (es)
CA (1) CA2859271A1 (es)
MX (1) MX351093B (es)
RU (1) RU2629114C2 (es)
WO (1) WO2013117512A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104114549A (zh) 2012-02-17 2014-10-22 霍夫曼-拉罗奇有限公司 新型吡咯烷衍生物
CN109053524A (zh) * 2018-09-11 2018-12-21 山东谛爱生物技术有限公司 一种N-Boc-3-羟基氮杂环丁烷的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0419235D0 (en) * 2004-08-28 2004-09-29 Astrazeneca Ab Compounds
WO2010007427A1 (en) * 2008-07-16 2010-01-21 Astrazeneca Ab Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases
WO2010121918A1 (en) * 2009-04-20 2010-10-28 F. Hoffmann-La Roche Ag Proline derivatives as cathepsin inhibitors
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives

Also Published As

Publication number Publication date
KR20140120902A (ko) 2014-10-14
CA2859271A1 (en) 2013-08-15
JP6096808B2 (ja) 2017-03-15
US20130210799A1 (en) 2013-08-15
RU2629114C2 (ru) 2017-08-24
CN104093713B (zh) 2016-11-02
CN104093713A (zh) 2014-10-08
JP2015509484A (ja) 2015-03-30
EP2812322A1 (en) 2014-12-17
RU2014133987A (ru) 2016-03-27
EP2812322B1 (en) 2017-12-06
US8822505B2 (en) 2014-09-02
MX351093B (es) 2017-10-02
WO2013117512A1 (en) 2013-08-15
BR112014019180A8 (pt) 2017-07-11
MX2014009451A (es) 2014-10-23
BR112014019180A2 (es) 2017-06-20

Similar Documents

Publication Publication Date Title
AR108745A1 (es) Derivados de oxadiazol microbiocidas
AR099511A1 (es) Derivados del ácido piridin-3-ilacético como inhibidores de la replicación del virus de inmunodeficiencia humana
AR093805A1 (es) Derivados de piridina agonistas del receptor 2 de cannabinoides
ES2531274T3 (es) Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
AR099932A1 (es) Derivados de piridina
AR063723A1 (es) 5-oxo-5,8-dihidro-piridopirimidinas inhibidoras de c-fms quinasas, composiciones farmaceuticas que las contienen y usos como agentes anticancer, en enfermedades cardiovasculares y procesos inflamatorios
AR094452A1 (es) COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
ES2659397T3 (es) 2-azabicíclicos sustituidos y su uso como moduladores receptores de orexinas
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR099933A1 (es) Derivados heterocíclicos de piridina agonistas de cb2
AR093804A1 (es) Derivados de pirazina agonistas de receptores cb2
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR095422A1 (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
AR095721A1 (es) Derivados de piridina
AR090587A1 (es) Compuestos triciclicos sustituidos con actividad hacia los receptores ep1
AR101392A1 (es) COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2
ECSP11010901A (es) Compuestos de amida útiles en terapia
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR088625A1 (es) Derivados de aril-quinolina
AR092973A1 (es) Benzamidas
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR096152A1 (es) Derivados de purina

Legal Events

Date Code Title Description
FB Suspension of granting procedure